Disorders such as inflammatory bowel disease (IBD) and celiac disease (CeD) result in intestinal hyperpermeability or 'leaky' gut. The increased permeability of the intestinal barrier allows microbial metabolites, toxins, and pathogens to infiltrate the bloodstream and extraintestinal tissues, causing systemic inflammation. Despite differences in aetiology and pathophysiology, IBD and CeD share several extraintestinal manifestations such as neuroinflammation, neurological and psychiatric manifestations, and sensorineural hearing loss (SNHL). This narrative review focuses on the association between intestinal hyperpermeability with the brain and inner ear diseases. We postulate that the microbial metabolites and pathogens released from the gut increase the permeability of natural barriers, such as the blood-brain barrier (BBB) and blood-labyrinth barrier (BLB). The barrier breakdown allows the spreading of inflammatory processes to the brain and inner ear, leading to disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.31083/j.fbe1402008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Probiotic and postbiotic interference exhibit anti-adhesion effects against clinical methicillin-resistant Staphylococcus aureus (MRSA) and impede MRSA-induced intestinal epithelial hyper-permeability in HT-29 cell line.
Microb Pathog
December 2024
Molecular Biology Unit, Dairy Microbiology Division, ICAR-National Dairy Research Institute, Karnal, 132001, Haryana, India; Dairy Bacteriology Section, Southern Regional Station, ICAR-National Dairy Research Institute, Adugodi, 560030, Bengaluru, Karnataka, India. Electronic address:
This study investigates the dynamics of MRSA de-colonization on HT-29 cell line using effective strategies like probiotics and postbiotics. Exploring novel alternatives to combat infections caused by antibiotic-resistant pathogens is an urgent need. Harnessing the antagonistic properties of live probiotics and their heat-killed preparations (postbiotics) to curb the growth of AMR pathogens represents a promising and essential area of contemporary research.
View Article and Find Full Text PDF1,25-dihydroxyvitamin D3 regulates enteroglial bioactivity through butyric acid pathway in a high-fat diet mouse model.
J Steroid Biochem Mol Biol
December 2024
The First Clinical Medical College, Guangdong Medical University, China; Department I of Gastrointestinal Surgery, Affiliated Maoming Hospital, Southern Medical University, China; Department I of Gastrointestinal Surgery, Maoming People's Hospital, Maoming City, China.
1,25-dihydroxyvitamin D3 (1,25(OH)2D3), affects enteric glial cells (EGCs) activity, but the mechanism is still unknown. The current study aimed to explore whether 1,25(OH)2D3 could regulate EGCs activity via butyrate pathway in a high-fat diet model. Male C57BL/6 J mice were fed with standard diet (SDD), or vitamin-D-deficient diet (VDD), or high-fat diet (HFD), or HFD plus sodium butyrate (SBR), or HFD plus 1,25(OH)2D3, or HFD plus S100B inhibitor ONO-2506 in vivo.
View Article and Find Full Text PDFIntestinal epithelial-specific occludin deletion worsens gut permeability and survival following sepsis.
Shock
December 2024
Department of Surgery and Emory Critical Care Center, Emory University, School of Medicine, Atlanta, Georgia, USA.
Article Synopsis
- - Sepsis leads to increased intestinal permeability, which is linked to higher mortality rates; occludin, a tight junction protein, is crucial for maintaining the intestinal barrier.
- - Research comparing occludin knockout mice and wild-type controls demonstrated that occludin KOIEC mice experienced significantly increased intestinal permeability only under septic conditions, without changes in other permeability pathways.
- - The occludin-deficient mice showed elevated inflammatory cytokines and higher mortality rates after sepsis, highlighting occludin's essential role in gut barrier function and survival, suggesting potential therapeutic approaches to enhance occludin function in sepsis treatment.
Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function.
World J Gastroenterol
November 2024
Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
Article Synopsis
- The article by Koizumi examines therapeutic targets for fibrosis in alcohol-related liver disease (ALD) and highlights elafibranor (EFN) as a dual agonist for PPARα and PPARδ.
- EFN, currently in phase III trials for other liver diseases, shows promise in reducing hepatic steatosis and fibrosis in ALD by activating PPARα and promoting fat metabolism.
- Additionally, EFN improves the gut-liver axis and intestinal barrier function, alleviating inflammation and contributing to overall liver health.
Intestinal Permeability In Subjects With Rheumatoid Arthritis: A Critical Therapeutic Priority.
Integr Med (Encinitas)
November 2024
VP and National Director of Medical Services, AndHealth, Columbus, Ohio; Associate Professor, Andrew Weil Center for Integrative Medicine, University of Arizona College of Medicine, Tucson, Arizona.
Article Synopsis
- Rheumatoid arthritis is recognized as part of a group of systemic autoimmune diseases, all sharing similar immune-signaling pathways despite having unique symptoms.
- Advances in treatment have focused on blocking inflammatory mediators like cytokines and JAK inhibitors but have seen less progress in targeting the root causes of inflammation, such as leaky gut and gut microbiota imbalances.
- The review highlights how issues with intestinal permeability are linked to several chronic conditions, including rheumatoid arthritis, suggesting that improving gut health could help patients manage their symptoms and achieve remission.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!